Your browser doesn't support javascript.
loading
Extended-Release Mixed Amphetamine Salts for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder: A Pilot, Randomized Double-Blind, Placebo-Controlled Trial.
Levin, Frances R; Mariani, John J; Pavlicova, Martina; Choi, C Jean; Basaraba, Cale; Mahony, Amy L; Brooks, Daniel J; Brezing, Christina A; Naqvi, Nasir.
Afiliación
  • Levin FR; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, NY, USA.
  • Mariani JJ; Department of Psychiatry, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY, USA.
  • Pavlicova M; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, NY, USA.
  • Choi CJ; Department of Psychiatry, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY, USA.
  • Basaraba C; Department of Biostatistics, Columbia University, New York, NY, USA.
  • Mahony AL; Division of Biostatistics, New York State Psychiatric Institute, New York, NY, USA.
  • Brooks DJ; Division of Biostatistics, New York State Psychiatric Institute, New York, NY, USA.
  • Brezing CA; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, NY, USA.
  • Naqvi N; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, NY, USA.
J Atten Disord ; 28(11): 1467-1481, 2024 Sep.
Article en En | MEDLINE | ID: mdl-39051597
ABSTRACT

OBJECTIVE:

To determine if treatment of co-occurring adult ADHD and Cannabis Use Disorder (CUD) with extended-release mixed amphetamine salts (MAS-ER) would be effective at improving ADHD symptoms and promoting abstinence.

METHOD:

A 12-week randomized, double-blind, two-arm pilot feasibility trial of adults with comorbid ADHD and CUD (n = 28) comparing MAS-ER (80 mg) to placebo. Main

outcomes:

ADHD ≥30% symptom reduction, measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS). CUD Abstinence during last 2 observed weeks of maintenance phase.

RESULTS:

Overall, medication was well-tolerated. There was no significant difference in ADHD symptom reduction (MAS-ER 83.3%; placebo 71.4%; p = .65) or cannabis abstinence (MAS-ER 15.4%; placebo 0%; p = .27). MAS-ER group showed a significant decrease in weekly cannabis use days over time compared to placebo (p < .0001).

CONCLUSIONS:

MAS-ER was generally well-tolerated. The small sample size precluded a determination of MAS-ER's superiority reducing ADHD symptoms or promoting abstinence. Notably, MAS-ER significantly reduced weekly days of use over time.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastorno por Déficit de Atención con Hiperactividad / Abuso de Marihuana / Preparaciones de Acción Retardada / Estimulantes del Sistema Nervioso Central Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Atten Disord Asunto de la revista: PSICOLOGIA / PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastorno por Déficit de Atención con Hiperactividad / Abuso de Marihuana / Preparaciones de Acción Retardada / Estimulantes del Sistema Nervioso Central Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Atten Disord Asunto de la revista: PSICOLOGIA / PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos